​

Silexion Therapeutics Stock (NASDAQ:SLXN)

FinancialsChart
Silexion Therapeutics by TradingView

Previous Close

$3.54

52W Range

$3.10 - $63.45

50D Avg

$5.03

200D Avg

$12.78

Market Cap

$1.87M

Avg Vol (3M)

$505.19K

Beta

-0.07

Div Yield

-

SLXN Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

11

IPO Date

Aug 16, 2024

Website

SLXN Performance

SLXN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income-$-4.68M$-3.86M
Net Income$16.51M$-4.94M$-3.21M
EBITDA-$-4.64M$-3.80M
Basic EPS-$-0.61$-0.39
Diluted EPS-$-0.61$-0.39

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
SPRCSciSparc Ltd.
CARMCarisma Therapeutics, Inc.
JSPRJasper Therapeutics, Inc.
GTBPGT Biopharma, Inc.
ONCOOnconetix, Inc.
REVBRevelation Biosciences, Inc.
INDPIndaptus Therapeutics, Inc.
SLRXSalarius Pharmaceuticals, Inc.
ENVBEnveric Biosciences, Inc.